vs

Side-by-side financial comparison of IRONWOOD PHARMACEUTICALS INC (IRWD) and Plymouth Industrial REIT, Inc. (PLYM). Click either name above to swap in a different company.

Plymouth Industrial REIT, Inc. is the larger business by last-quarter revenue ($51.2M vs $47.7M, roughly 1.1× IRONWOOD PHARMACEUTICALS INC). IRONWOOD PHARMACEUTICALS INC runs the higher net margin — -4.8% vs -106.3%, a 101.5% gap on every dollar of revenue. On growth, Plymouth Industrial REIT, Inc. posted the faster year-over-year revenue change (-1.4% vs -47.3%). Over the past eight quarters, Plymouth Industrial REIT, Inc.'s revenue compounded faster (0.4% CAGR vs -20.2%).

Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.

Plymouth Industrial REIT, Inc. is a real estate investment trust focused on owning, operating, and acquiring high-quality industrial properties including distribution centers, warehouses, and light industrial facilities across key U.S. logistics hubs. It serves tenants in e-commerce, retail, manufacturing, and third-party logistics sectors, supporting diverse business supply chain needs.

IRWD vs PLYM — Head-to-Head

Bigger by revenue
PLYM
PLYM
1.1× larger
PLYM
$51.2M
$47.7M
IRWD
Growing faster (revenue YoY)
PLYM
PLYM
+45.9% gap
PLYM
-1.4%
-47.3%
IRWD
Higher net margin
IRWD
IRWD
101.5% more per $
IRWD
-4.8%
-106.3%
PLYM
Faster 2-yr revenue CAGR
PLYM
PLYM
Annualised
PLYM
0.4%
-20.2%
IRWD

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
IRWD
IRWD
PLYM
PLYM
Revenue
$47.7M
$51.2M
Net Profit
$-2.3M
$-54.4M
Gross Margin
Operating Margin
14.3%
-102.5%
Net Margin
-4.8%
-106.3%
Revenue YoY
-47.3%
-1.4%
Net Profit YoY
-200.9%
-248.5%
EPS (diluted)
$0.01
$-1.23

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRWD
IRWD
PLYM
PLYM
Q4 25
$47.7M
Q3 25
$122.1M
$51.2M
Q2 25
$85.2M
$47.2M
Q1 25
$41.1M
$45.6M
Q4 24
$90.5M
$47.6M
Q3 24
$91.6M
$51.9M
Q2 24
$94.4M
$48.7M
Q1 24
$74.9M
$50.2M
Net Profit
IRWD
IRWD
PLYM
PLYM
Q4 25
$-2.3M
Q3 25
$40.1M
$-54.4M
Q2 25
$23.6M
$-6.1M
Q1 25
$-37.4M
$5.8M
Q4 24
$2.3M
$147.4M
Q3 24
$3.6M
$-15.6M
Q2 24
$-860.0K
$1.3M
Q1 24
$-4.2M
$6.2M
Operating Margin
IRWD
IRWD
PLYM
PLYM
Q4 25
14.3%
Q3 25
61.8%
-102.5%
Q2 25
53.2%
-10.3%
Q1 25
-70.7%
Q4 24
34.8%
Q3 24
28.0%
-29.6%
Q2 24
26.5%
2.7%
Q1 24
14.7%
Net Margin
IRWD
IRWD
PLYM
PLYM
Q4 25
-4.8%
Q3 25
32.8%
-106.3%
Q2 25
27.7%
-12.9%
Q1 25
-90.9%
12.8%
Q4 24
2.5%
309.9%
Q3 24
4.0%
-30.1%
Q2 24
-0.9%
2.7%
Q1 24
-5.6%
12.4%
EPS (diluted)
IRWD
IRWD
PLYM
PLYM
Q4 25
$0.01
Q3 25
$0.23
$-1.23
Q2 25
$0.14
$-0.14
Q1 25
$-0.23
$0.13
Q4 24
$0.03
$3.24
Q3 24
$0.02
$-0.35
Q2 24
$-0.01
$0.03
Q1 24
$-0.03
$0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRWD
IRWD
PLYM
PLYM
Cash + ST InvestmentsLiquidity on hand
$215.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$-261.8M
$470.1M
Total Assets
$396.9M
$1.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRWD
IRWD
PLYM
PLYM
Q4 25
$215.5M
Q3 25
$140.4M
Q2 25
$92.9M
Q1 25
$108.5M
Q4 24
$88.6M
Q3 24
$88.2M
Q2 24
$105.5M
Q1 24
$121.5M
Total Debt
IRWD
IRWD
PLYM
PLYM
Q4 25
Q3 25
$199.5M
Q2 25
$199.3M
Q1 25
$199.2M
Q4 24
$199.0M
$646.4M
Q3 24
$198.8M
Q2 24
$198.6M
Q1 24
$398.3M
Stockholders' Equity
IRWD
IRWD
PLYM
PLYM
Q4 25
$-261.8M
Q3 25
$-264.2M
$470.1M
Q2 25
$-308.2M
$539.6M
Q1 25
$-334.1M
$571.0M
Q4 24
$-301.3M
$579.5M
Q3 24
$-311.3M
$436.5M
Q2 24
$-321.7M
$475.2M
Q1 24
$-330.5M
$484.6M
Total Assets
IRWD
IRWD
PLYM
PLYM
Q4 25
$396.9M
Q3 25
$396.1M
$1.6B
Q2 25
$342.9M
$1.6B
Q1 25
$327.2M
$1.4B
Q4 24
$350.9M
$1.4B
Q3 24
$389.5M
$1.5B
Q2 24
$395.6M
$1.4B
Q1 24
$438.8M
$1.4B
Debt / Equity
IRWD
IRWD
PLYM
PLYM
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
1.12×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRWD
IRWD
PLYM
PLYM
Operating Cash FlowLast quarter
$74.6M
$20.0M
Free Cash FlowOCF − Capex
$74.6M
FCF MarginFCF / Revenue
156.3%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$127.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRWD
IRWD
PLYM
PLYM
Q4 25
$74.6M
Q3 25
$47.6M
$20.0M
Q2 25
$-15.1M
$23.4M
Q1 25
$20.0M
$15.6M
Q4 24
$15.2M
$96.1M
Q3 24
$9.9M
$17.6M
Q2 24
$33.5M
$19.9M
Q1 24
$45.0M
$16.6M
Free Cash Flow
IRWD
IRWD
PLYM
PLYM
Q4 25
$74.6M
Q3 25
$47.6M
Q2 25
$-15.1M
Q1 25
$19.9M
Q4 24
Q3 24
$9.9M
Q2 24
$33.4M
Q1 24
$44.9M
FCF Margin
IRWD
IRWD
PLYM
PLYM
Q4 25
156.3%
Q3 25
39.0%
Q2 25
-17.7%
Q1 25
48.4%
Q4 24
Q3 24
10.8%
Q2 24
35.4%
Q1 24
60.0%
Capex Intensity
IRWD
IRWD
PLYM
PLYM
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.1%
Q4 24
0.0%
Q3 24
0.0%
Q2 24
0.1%
Q1 24
0.1%
Cash Conversion
IRWD
IRWD
PLYM
PLYM
Q4 25
Q3 25
1.19×
Q2 25
-0.64×
Q1 25
2.67×
Q4 24
6.74×
0.65×
Q3 24
2.71×
Q2 24
15.12×
Q1 24
2.67×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons